Literature DB >> 31005174

Using biparametric MRI radiomics signature to differentiate between benign and malignant prostate lesions.

Min Xu1, Mengjie Fang2, Jian Zou3, Shudong Yang4, Dongdong Yu2, Lianzhen Zhong2, Chaoen Hu2, Yali Zang2, Di Dong5, Jie Tian6, Xiangming Fang7.   

Abstract

PURPOSE: To investigate the efficiency of radiomics signature in discriminating between benign and malignant prostate lesions with similar biparametric magnetic resonance imaging (bp-MRI) findings. EXPERIMENTAL
DESIGN: Our study consisted of 331 patients underwent bp-MRI before pathological examination from January 2013 to November 2016. Radiomics features were extracted from peripheral zone (PZ), transition zone (TZ), and lesion areas segmented on images obtained by T2-weighted imaging (T2WI), diffusion-weighted imaging (DWI), and its derivative apparent-diffusion coefficient (ADC) imaging. The individual prediction model, built using the clinical data and biparametric MRI features (Bp signature), was prepared using data of 232 patients and validated using data of 99 patients. The predictive performance was calculated and demonstrated using receiver operating characteristic (ROC) curves, calibration curves, and decision curves.
RESULTS: The Bp signature, based on the six selected radiomics features of bp-MRI, showed better discrimination in the validation cohort (area under the curve [AUC], 0.92) than on each subcategory images (AUC, 0.81 on T2WI; AUC, 0.77 on DWI; AUC, 0.89 on ADC). The differential diagnostic efficiency was poorer with the clinical model (AUC, 0.73), built using the selected independent clinical risk factors with statistical significance (P < 0.05), than with the Bp signature. Discrimination efficiency improved when including the Bp signature and clinical factors [i.e., the individual prediction model (AUC, 0.93)].
CONCLUSION: The Bp signature, based on bp-MRI, performed better than each single imaging modality. The individual prediction model including the radiomics signatures and clinical factors showed better preoperative diagnostic performance, which could contribute to clinical individualized treatment.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Biparametric magnetic resonance imaging; Medical imaging; Prostate cancer; Radiomics

Mesh:

Year:  2019        PMID: 31005174     DOI: 10.1016/j.ejrad.2019.02.032

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  13 in total

1.  Evaluation of the Efficiency of MRI-Based Radiomics Classifiers in the Diagnosis of Prostate Lesions.

Authors:  Linghao Li; Lili Gu; Bin Kang; Jiaojiao Yang; Ying Wu; Hao Liu; Shasha Lai; Xueting Wu; Jian Jiang
Journal:  Front Oncol       Date:  2022-07-05       Impact factor: 5.738

2.  Machine learning-based prediction of invisible intraprostatic prostate cancer lesions on 68 Ga-PSMA-11 PET/CT in patients with primary prostate cancer.

Authors:  Zhilong Yi; Siqi Hu; Xiaofeng Lin; Qiong Zou; MinHong Zou; Zhanlei Zhang; Lei Xu; Ningyi Jiang; Yong Zhang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-11-30       Impact factor: 10.057

3.  Bi-parametric magnetic resonance imaging based radiomics for the identification of benign and malignant prostate lesions: cross-vendor validation.

Authors:  Xuefu Ji; Jiayi Zhang; Yuguo Tang; Wei Xia; Wei Shi; Dong He; Jie Bao; Xuedong Wei; Yuhua Huang; Yangchuan Liu; Jyh-Cheng Chen; Xin Gao
Journal:  Phys Eng Sci Med       Date:  2021-06-01

Review 4.  Imaging for Target Delineation and Treatment Planning in Radiation Oncology: Current and Emerging Techniques.

Authors:  Sonja Stieb; Brigid McDonald; Mary Gronberg; Grete May Engeseth; Renjie He; Clifton David Fuller
Journal:  Hematol Oncol Clin North Am       Date:  2019-09-17       Impact factor: 3.722

5.  Radiomics Based on Contrast-Enhanced MRI in Differentiation Between Fat-Poor Angiomyolipoma and Hepatocellular Carcinoma in Noncirrhotic Liver: A Multicenter Analysis.

Authors:  Xiangtian Zhao; Yukun Zhou; Yuan Zhang; Lujun Han; Li Mao; Yizhou Yu; Xiuli Li; Mengsu Zeng; Mingliang Wang; Zaiyi Liu
Journal:  Front Oncol       Date:  2021-10-13       Impact factor: 6.244

6.  MRI Based Radiomics Compared With the PI-RADS V2.1 in the Prediction of Clinically Significant Prostate Cancer: Biparametric vs Multiparametric MRI.

Authors:  Tong Chen; Zhiyuan Zhang; Shuangxiu Tan; Yueyue Zhang; Chaogang Wei; Shan Wang; Wenlu Zhao; Xusheng Qian; Zhiyong Zhou; Junkang Shen; Yakang Dai; Jisu Hu
Journal:  Front Oncol       Date:  2022-01-20       Impact factor: 6.244

Review 7.  Artificial Intelligence Based Algorithms for Prostate Cancer Classification and Detection on Magnetic Resonance Imaging: A Narrative Review.

Authors:  Jasper J Twilt; Kicky G van Leeuwen; Henkjan J Huisman; Jurgen J Fütterer; Maarten de Rooij
Journal:  Diagnostics (Basel)       Date:  2021-05-26

8.  The Role of [18F]Fluciclovine PET/CT in the Characterization of High-Risk Primary Prostate Cancer: Comparison with [11C]Choline PET/CT and Histopathological Analysis.

Authors:  Lucia Zanoni; Riccardo Mei; Lorenzo Bianchi; Francesca Giunchi; Lorenzo Maltoni; Cristian Vincenzo Pultrone; Cristina Nanni; Irene Bossert; Antonella Matti; Riccardo Schiavina; Michelangelo Fiorentino; Cristina Fonti; Filippo Lodi; Antonietta D'Errico; Eugenio Brunocilla; Stefano Fanti
Journal:  Cancers (Basel)       Date:  2021-03-29       Impact factor: 6.639

Review 9.  Radiomics in prostate cancer imaging for a personalized treatment approach - current aspects of methodology and a systematic review on validated studies.

Authors:  Simon K B Spohn; Alisa S Bettermann; Fabian Bamberg; Matthias Benndorf; Michael Mix; Nils H Nicolay; Tobias Fechter; Tobias Hölscher; Radu Grosu; Arturo Chiti; Anca L Grosu; Constantinos Zamboglou
Journal:  Theranostics       Date:  2021-07-06       Impact factor: 11.556

10.  MRI-Based Radiomics Models for Predicting Risk Classification of Gastrointestinal Stromal Tumors.

Authors:  Haijia Mao; Bingqian Zhang; Mingyue Zou; Yanan Huang; Liming Yang; Cheng Wang; PeiPei Pang; Zhenhua Zhao
Journal:  Front Oncol       Date:  2021-05-10       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.